ASTX295 + Olaparib: A Targeted Strategy for BRCA2‑Mutant, TP53‑Wild‑Type Cancers

ASTX295 is an experimental cancer drug that works by turning on a powerful tumor‑suppressor protein called p53 in cancer cells that still have a normal version of the gene TP53. In many cancers, p53 is not broken but is kept switched off by another protein called MDM2, which constantly tags p53 for destruction. ASTX295 blocks the interaction between p53 and MDM2, so p53 builds up inside the cell and becomes active. Activated p53 then turns on a set of genes that decide what the cell should do in response to stress, including stopping the cell cycle, entering permanent dormancy, or triggering programmed cell death, also known as apoptosis.

In tumors where TP53 is wild‑type, ASTX295 can push cancer cells toward apoptosis when they are already under stress, for example from DNA damage. On its own, ASTX295 has shown anti‑tumor activity, but its effect as a single agent has been modest in clinical trials. However, when combined with other drugs that increase DNA damage or block DNA repair, the synergy becomes much stronger. One of the most promising combinations is with the PARP inhibitor olaparib. PARP inhibitors prevent the repair of single‑strand DNA breaks, which are converted into double‑strand breaks during DNA replication, especially in cells with defects in homologous recombination, such as BRCA2‑mutant tumors. This creates persistent DNA damage that strongly activates p53.

In TP53‑wild‑type cells, PARP inhibition alone can turn on p53 and drive p21‑mediated cell‑cycle arrest, which often allows cells to survive and recover. When ASTX295 is added, p53 cannot be turned off by MDM2, so its activity stays high while the cell is under heavy genotoxic stress. This combination shifts the balance from survival to apoptosis, leading to significantly more cancer cell death than either drug alone. Preclinical studies using genome‑wide drug‑CRISPR screens have shown that components of DNA repair pathways, including PARP1, strongly sensitize cells to ASTX295. A proprietary biomarker pipeline called PRIME has identified robust combination synergy and reduced viability specifically in BRCA2‑mutant solid tumor cell lines treated with ASTX295 plus olaparib.

In animal models, ASTX295 combined with olaparib has demonstrated superior anti‑tumor activity in BRCA2‑mutant, TP53‑wild‑type xenografts, including both cell‑line‑derived and patient‑derived tumors. The combination produces longer control of tumor growth and even tumor regressions at doses that are well tolerated, suggesting it may be both effective and manageable in patients. This has led to the development of MOS101, a clinical program that pairs ASTX295 with olaparib in biomarker‑selected solid tumors, with a focus on patients whose cancers have intact TP53 and defects in homologous recombination, such as BRCA2 mutations.

The reason this strategy is limited to TP53‑wild‑type tumors is that the entire mechanism depends on p53 being functional. If TP53 is mutated or missing, blocking MDM2 cannot restore normal tumor‑suppressor activity, so ASTX295 has little or no effect. Data from in vitro and early clinical work (Phase 1 trial – NCT03975387) show that ASTX295 is highly active in TP53‑wild‑type cells but shows minimal activity in TP53‑mutant lines, reinforcing the need for careful patient selection.

Overall, ASTX295 represents a next‑generation MDM2 antagonist that aims to exploit a fundamental vulnerability in TP53‑wild‑type cancers: their dependence on MDM2 to keep p53 under control. By combining ASTX295 with DNA‑damaging or repair‑blocking agents, researchers hope to push stressed cancer cells over the edge into apoptosis rather than simply arresting them, potentially leading to deeper and more durable responses in carefully selected patients.

Source.